Dimensional Fund Advisors LP trimmed its position in shares of Biogen Inc. (NASDAQ:BIIB) by 0.2% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 518,627 shares of the biotechnology company’s stock after selling 1,219 shares during the quarter. Dimensional Fund Advisors LP owned 0.25% of Biogen worth $140,739,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Botty Investors LLC raised its position in shares of Biogen by 75.0% during the second quarter. Botty Investors LLC now owns 11,232 shares of the biotechnology company’s stock worth $3,048,000 after purchasing an additional 4,812 shares during the period. Savant Capital LLC raised its position in shares of Biogen by 3.7% during the first quarter. Savant Capital LLC now owns 846 shares of the biotechnology company’s stock worth $231,000 after purchasing an additional 30 shares during the period. BB&T Securities LLC raised its position in shares of Biogen by 25.0% during the second quarter. BB&T Securities LLC now owns 12,989 shares of the biotechnology company’s stock worth $3,524,000 after purchasing an additional 2,598 shares during the period. Vanguard Group Inc. raised its position in shares of Biogen by 2.4% during the first quarter. Vanguard Group Inc. now owns 14,352,490 shares of the biotechnology company’s stock worth $3,924,258,000 after purchasing an additional 342,568 shares during the period. Finally, Karp Capital Management Corp acquired a new position in shares of Biogen during the first quarter worth approximately $26,224,000. 87.65% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Dimensional Fund Advisors LP Lowers Stake in Biogen Inc. (BIIB)” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2017/09/30/dimensional-fund-advisors-lp-lowers-stake-in-biogen-inc-biib.html.

In other news, EVP Susan H. Alexander sold 4,974 shares of the company’s stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $290.01, for a total value of $1,442,509.74. Following the completion of the transaction, the executive vice president now owns 22,258 shares of the company’s stock, valued at $6,455,042.58. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Susan H. Alexander sold 7,758 shares of the company’s stock in a transaction dated Wednesday, July 19th. The stock was sold at an average price of $285.00, for a total value of $2,211,030.00. Following the completion of the transaction, the executive vice president now directly owns 27,232 shares of the company’s stock, valued at approximately $7,761,120. The disclosure for this sale can be found here. Corporate insiders own 0.25% of the company’s stock.

Shares of Biogen Inc. (BIIB) opened at 313.12 on Friday. Biogen Inc. has a 12-month low of $244.28 and a 12-month high of $330.00. The firm has a 50 day moving average price of $300.47 and a 200 day moving average price of $278.47. The stock has a market cap of $66.20 billion, a PE ratio of 20.55 and a beta of 0.77.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Tuesday, July 25th. The biotechnology company reported $5.04 earnings per share for the quarter, topping analysts’ consensus estimates of $4.36 by $0.68. The firm had revenue of $3.08 billion during the quarter, compared to analyst estimates of $2.81 billion. Biogen had a return on equity of 37.42% and a net margin of 28.10%. The business’s quarterly revenue was up 6.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $5.21 earnings per share. On average, equities analysts expect that Biogen Inc. will post $21.51 EPS for the current year.

A number of equities research analysts recently commented on the company. Mizuho reissued a “neutral” rating and issued a $319.00 price target (up from $274.00) on shares of Biogen in a research report on Wednesday, September 13th. BMO Capital Markets increased their price target on Biogen from $328.00 to $377.00 and gave the company a “market perform” rating in a research report on Wednesday, September 13th. Vetr raised Biogen from a “hold” rating to a “buy” rating and set a $346.83 price target for the company in a research report on Thursday, September 7th. Royal Bank Of Canada assumed coverage on Biogen in a research report on Thursday, September 14th. They issued a “sector perform” rating and a $319.00 price target for the company. Finally, ValuEngine lowered Biogen from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Fourteen analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $328.16.

About Biogen

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Stock Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related stocks with our FREE daily email newsletter.